Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease PatientsJuly 26th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients A biopharmaceutical company announced the results of a Phase 1b of CERC-002.Article from GlobeNewswireShare This Story, Choose Your PlatformFacebookXLinkedInPinterestEmail Related Posts Choosing The Greater Philadelphia Region for Business Expansion Connecting Global Innovators to Greater Philadelphia Stories From Our Region: December 2025 Stories From Our Region: November 2025 Stories From Our Region: September 2025
